NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Outpace Bio

Outpace Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.outpacebio.com/

Last Round

Series B

Aug 1, 2024

Total Funding Raised

$174M

Company Overview

Outpace Bio is a biotechnology company that develops AI-powered protein design technologies to engineer immune cells for more effective and safer cell therapies targeting solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

computational protein designcell therapysolid tumorsCAR-T therapyAI protein designsynthetic biologyprotein engineeringnext generation cell therapiesprogrammable medicinedrug discovery platformimmunotherapyde novo protein designbiotech partnershipstumor microenvironmentoncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Outpace Bio Comparables

Compare Outpace Bio with similar companies based on industry and business-model similarity.

Outpace Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ArsenalBio
78%
LabGenius Therapeutics
74%
Evozyne
73%

Outpace Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 1, 2024
Series AMar 31, 2021

Key People

Founding team and executive leadership

Scott Boyken

Co-Founder, Chief Technology Officer

Founding Team

Marc Lajoie

Co-founder, Chief Executive Officer

Founding Team

Outpace Bio Investors

Notable investors and investment history

Outpace Bio investors
InvestorRounds
Surveyor CapitalSeries B
RA Capital ManagementSeries B
WRF CapitalSeries A, Series B
Playground GlobalSeries A, Series B
ARTIS VenturesSeries B, Series A
Washington Research Foundation CapitalSeries A, Series B
Abstract VenturesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 4, 2025

    Lead candidate OPB-101 targeting ovarian cancer to begin dosing in 2025.

  • Aug 1, 2024

    $144M round led by RA Capital Management.

Outpace Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Outpace Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Outpace Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range73
Year Founded2020
Last FundingAug 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.